IL130246A0 - Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy - Google Patents

Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy

Info

Publication number
IL130246A0
IL130246A0 IL13024697A IL13024697A IL130246A0 IL 130246 A0 IL130246 A0 IL 130246A0 IL 13024697 A IL13024697 A IL 13024697A IL 13024697 A IL13024697 A IL 13024697A IL 130246 A0 IL130246 A0 IL 130246A0
Authority
IL
Israel
Prior art keywords
texaphyrins
texaphyrin
therapy
ocular
photosensitive
Prior art date
Application number
IL13024697A
Other languages
English (en)
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of IL130246A0 publication Critical patent/IL130246A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13024697A 1996-12-11 1997-12-11 Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy IL130246A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76345196A 1996-12-11 1996-12-11
PCT/US1997/022661 WO1998025648A2 (en) 1996-12-11 1997-12-11 Use of a texaphyrin in ocular diagnosis and therapy

Publications (1)

Publication Number Publication Date
IL130246A0 true IL130246A0 (en) 2000-06-01

Family

ID=25067866

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13024697A IL130246A0 (en) 1996-12-11 1997-12-11 Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy

Country Status (12)

Country Link
EP (1) EP1005369B1 (de)
JP (1) JP2002512594A (de)
KR (1) KR20000057532A (de)
CN (1) CN1265039A (de)
AT (1) ATE240745T1 (de)
AU (1) AU730074B2 (de)
BR (1) BR9714642A (de)
CA (1) CA2278937A1 (de)
DE (1) DE69722263T2 (de)
IL (1) IL130246A0 (de)
NZ (1) NZ336113A (de)
WO (1) WO1998025648A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6280703B1 (en) * 1997-03-13 2001-08-28 Mallinckrodt Inc. Simultaneous multimodal measurement of physiological function
US6178346B1 (en) 1998-10-23 2001-01-23 David C. Amundson Infrared endoscopic imaging in a liquid with suspended particles: method and apparatus
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US7073510B2 (en) 2000-02-11 2006-07-11 The General Hospital Corporation Photochemical tissue bonding
US8215314B2 (en) 2000-02-11 2012-07-10 The General Hospital Corporation Photochemical tissue bonding
KR20020060020A (ko) * 2001-01-09 2002-07-16 박종윤 고출력 반도체 레이저 다이오드(high power semiconductorlaser diode)를 이용한 광역동 치료 및 진단(photodynamictreatment / diagnosis)용 의료용 레이저 기구
MXPA05011701A (es) 2003-05-01 2006-01-23 Millennium Diet And Nutriceuti Medicion de la distribucion del pigmento macular.
WO2006015016A2 (en) * 2004-07-30 2006-02-09 Massachusetts Eye And Ear Infirmary Photodynamic therapy and compositions for treating ocular glaucoma
US7468434B2 (en) * 2004-12-22 2008-12-23 The University Of Hong Kong Diazene-bridge crown ether lithium compounds and methods for their use
WO2008005514A2 (en) 2006-07-06 2008-01-10 The Trustees Of Columbia University In The City Of New York Polychromatic, diversely-sized particles for angiography
RU2387471C1 (ru) * 2008-08-12 2010-04-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ количественной оценки эффективности фотодинамической терапии хориоидальной неоваскуляризации
RU2395318C1 (ru) * 2009-01-15 2010-07-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения скрытых субретинальных неоваскулярных мембран
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
KR101894150B1 (ko) * 2016-11-15 2018-08-31 포항공과대학교 산학협력단 다광자 특성을 이용한 안과용 진단 및 치료장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
AU717193B2 (en) * 1996-03-26 2000-03-23 Pharmacyclics, Inc. Use of a texaphyrin in photodynamic therapy of pigment-related lesions
BR9710685A (pt) * 1996-06-04 2000-01-11 Pharmacyclics Inc Incorporação de membrana de texafirinas.

Also Published As

Publication number Publication date
WO1998025648A3 (en) 1999-12-09
ATE240745T1 (de) 2003-06-15
AU730074B2 (en) 2001-02-22
EP1005369B1 (de) 2003-05-21
CA2278937A1 (en) 1998-06-18
AU5897698A (en) 1998-07-03
EP1005369A2 (de) 2000-06-07
DE69722263D1 (de) 2003-06-26
NZ336113A (en) 2000-12-22
DE69722263T2 (de) 2004-04-08
KR20000057532A (ko) 2000-09-25
CN1265039A (zh) 2000-08-30
BR9714642A (pt) 2000-10-03
WO1998025648A2 (en) 1998-06-18
JP2002512594A (ja) 2002-04-23

Similar Documents

Publication Publication Date Title
WO1998025648A3 (en) Use of a texaphyrin in ocular diagnosis and therapy
CA2248087A1 (en) Improved vision through photodynamic therapy of the eye
Bressler et al. Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
NZ336568A (en) Photochemotherapeutic compositions
AP1750A (en) Methods for treating ocular neovascular diseases
WO2002062385A3 (en) Method to prevent vision loss
CA2400801A1 (en) Treatment of congestive heart failure by pretreated autologous blood
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
WO2002051433A3 (en) Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament
CA2311356A1 (en) Method for treating alzheimer's disease
WO2005070052A3 (en) Use of photodynamic therapy to enhance treatment with immuno-modulating agents
EP0665749A4 (de) Verfahren und zusammensetzung zur behandlung der parkinson-krankheit.
CA2185644A1 (en) Use of green porphyrins in ocular diagnosis and therapy
IL158032A (en) Metal substituted non centrosymmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostics
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
CA2281807A1 (en) Method of treating a tumor
WO2001035997A3 (en) Use of low-dose pdt to inhibit restenosis
TR200302008T4 (tr) Dış retina bozukluklarının tedavisine yönelik bir ilaç üretiminde beta-adrenoseptör antagonistlerin kullanımı.
RU96121849A (ru) Способ лечения амблиопии
RU93011688A (ru) Способ лечения диабетической ретинопатии
Andrawus et al. Light modulates ocular complications in an albino rat model of type 1 diabetes mellitus
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence